Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Sequencing » Illumina Snares First FDA Emergency Use Authorization for NGS-Based SARS-CoV-2 Test

Illumina Snares First FDA Emergency Use Authorization for NGS-Based SARS-CoV-2 Test

Jun 09, 2020
|
staff reporter

NEW YORK – Illumina said late Tuesday evening that its next-generation sequencing based test for COVID-19 has been issued Emergency Use Authorization by the US Food and Drug Administration, making it the first NGS test to receive such designation for detecting SARS-CoV-2.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

UK Funds Challenge Trial

The UK is investing £33.6 million into a controversial human SARS-CoV-2 challenge study, according to Reuters.

Watching the Changes

The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.

Max Planck, Nature Strike a Deal

Science reports that Max Planck and Nature have struck a deal for affiliated authors to publish papers that are accessible to the public as well as access Nature-branded journals.

PNAS Papers on Ancient Tibetan Animals, HNSCC Drug Response, More

In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.

Oct
21
Featured Webinar

Target Enrichment NGS Panel Outperforms the Gold Standard for Sequence and CNV Analysis

Sponsored by
Roche

Target enrichment has been a major driver behind the clinical adoption of next-generation sequencing (NGS) over the last decade because it simplifies analysis and provides a cost-effective method of massive parallel resequencing. It has not only replaced Sanger sequencing, but it is actively dispensing the need for parallel copy number variant (CNV) analysis using classic techniques.

Oct
22
Featured Webinar

Adoption of Broad NGS Profiling for HRR Deficiency: Looking Beyond BRCA, SNPs, and Indels

Sponsored by
Sophia Genetics

This webinar will share the Lorraine Cancer Institute's experience in implementing a novel targeted solution to accurately assess homologous recombination repair (HRR) deficiency by analyzing a series of genes, beyond BRCA, and calling multiple types of variants, including copy number variants (CNVs).

Oct
28
Featured Webinar

How Low Can You Go? Reduce Breeding Costs with an Optimized Genotyping and Analysis Strategy

Sponsored by
NRGene

Molecular breeding methods such as genomic selection and genome-wide association studies often require high-density genotypic data from many samples, but the cost and complexity of genotyping at this scale may be prohibitive.

Oct
29
Featured Webinar

How to Train Your DRAGEN for Pathology Informatics

Sponsored by
Illumina

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

What's Popular?

In Molecular Diagnostics

  1. CMS Colon Cancer Screening Memo Bodes Well for Assays in Development; Denies Epi ProColon

  2. Centogene Increases Full-Year Revenue Guidance; CEO Resigns

  3. FDA Reissues Emergency Use Authorization for Thermo Fisher Scientific COVID-19 Combo Kit

  4. Fluidigm Shares Rise on Selection of Saliva-Based COVID-19 Assay for Federal Surge Testing

  5. Interdisciplinary NIST Team Claims qPCR Improvements Using Unusual Math Tweaks

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.